Early access programme for MK-0518 integrase inhibitor

HIV Treat Bull - 2006 October;7(10):

As this issue of HTB went to press, a named patient programme (NPP) for MK-0518, an integrase inhibitor currently in Phase 3 development by Merck, was due to be launched in the UK, with expected availability in the UK from late October. The programme is also called EARMRK and started in the US on 11 September 2006.

Entry criteria for the programme include patients on a currently failing regimen with resistance to at least one drug in each of the three classes of oral antiretrovirals (RTI, NNRTI and PI) and who are at risk of clinical or immunologic progression. It is the responsibility of the clinician ‘to determine that they need such an investigational medication to construct a potentially viable regimen’.

Currently, the medical affairs department at Merck UK are directing doctors to Parexel, the contract research organisation responsible for conducting the programme, and to register patients in the US through these websites:

EARMRK, the expanded access research program from Merck

BENCHMARK HIV Investigational Studies

Merck in the UK can be contacted on 01992-467272 (main switchboard, ask for external affairs or medical information departments).

comment

Data presented at the IAC conference and reported in the September issue of HTB, together with further data form ICAAC reported in this issue, show MK-0518 to be potentially one of the most important new options for patients with drug resistance. [1]

Data in treatment naIve patients was presented at the 13th Conference on Retroviruses and OIs (CROI) earlier this year. [2]

MK-0518 needs to be used in combination with other drugs that are active. Currently, the only potential drug interaction with other ARVs is the investigational NNRTI etravirine (TMC-125).

Source: MSD press release

References:

1. Markowitz M, Nguyen B-Y, Gotuzzo E et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naIve HIV-1 infected patients. Late breaker abstract THLB0214. See HTB September 2006
http://www.i-base.info/htb/v7/htb7-9/Integrase.html
2. Grinsztejn B et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 13 CROI Abstract 159LB. See HTB March 2006.
http://www.i-base.info/htb/v7/htb7-3/Early.html

2006-10-10
IB060710-07

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.